Lupin falls 3% as USFDA issues 5 observations for Vizag facility

Shares of Lupin slipped 3 per cent to Rs 742 on the BSE on Monday in the intra-day trade after the drug company said it has received five observations from the US health regulator after inspection of its Vizag facility in Andhra Pradesh.

“The United States Food and Drug Administration (USFDA) carried out the inspection of the company’s Vizag API manufacturing facility between January 13, 2020 and January 17, 2020. The inspection for the API facility at Vizag closed with five 483 observations,” Lupin said in an exchange filing on Saturday.

“We are fully committed to adherence with